NZ331299A - Antibody variants with reduced affinity for a cell-surface antigen - Google Patents

Antibody variants with reduced affinity for a cell-surface antigen

Info

Publication number
NZ331299A
NZ331299A NZ331299A NZ33129997A NZ331299A NZ 331299 A NZ331299 A NZ 331299A NZ 331299 A NZ331299 A NZ 331299A NZ 33129997 A NZ33129997 A NZ 33129997A NZ 331299 A NZ331299 A NZ 331299A
Authority
NZ
New Zealand
Prior art keywords
antibody
cell
surface antigen
reduced affinity
therapeutic
Prior art date
Application number
NZ331299A
Other languages
English (en)
Inventor
Herman Waldmann
Lisa Kim Gilliland
Masahide Tone
Mark Raymond Frewin
Louise Walsh
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of NZ331299A publication Critical patent/NZ331299A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ331299A 1996-02-20 1997-02-20 Antibody variants with reduced affinity for a cell-surface antigen NZ331299A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants
PCT/GB1997/000472 WO1997031024A1 (en) 1996-02-20 1997-02-20 Antibody variants

Publications (1)

Publication Number Publication Date
NZ331299A true NZ331299A (en) 2000-05-26

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ331299A NZ331299A (en) 1996-02-20 1997-02-20 Antibody variants with reduced affinity for a cell-surface antigen

Country Status (11)

Country Link
US (2) US20020048578A1 (enExample)
EP (1) EP0970127B1 (enExample)
JP (1) JP4574750B2 (enExample)
AT (1) ATE373016T1 (enExample)
AU (1) AU723366B2 (enExample)
CA (1) CA2246715C (enExample)
DE (1) DE69738138T2 (enExample)
ES (1) ES2294793T3 (enExample)
GB (1) GB9603507D0 (enExample)
NZ (1) NZ331299A (enExample)
WO (1) WO1997031024A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0859841B1 (en) * 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
KR20060002896A (ko) * 2003-03-31 2006-01-09 기린 비루 가부시키가이샤 항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
NZ550815A (en) * 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
AU2006226192A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100197896A1 (en) * 2007-05-16 2010-08-05 Leung Shui-On Functional humanization of complementarity determining regions (cdrs)
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9494597B2 (en) * 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
EP3962926A4 (en) 2019-04-30 2022-11-23 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
KR100264218B1 (ko) * 1991-10-15 2000-08-16 그레이엄 브레레톤 관절의 T-세포 매개 염증의 치료용 CDw52-특이 항체
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
US8440190B2 (en) 2013-05-14
US20020048578A1 (en) 2002-04-25
AU723366B2 (en) 2000-08-24
EP0970127B1 (en) 2007-09-12
JP4574750B2 (ja) 2010-11-04
ATE373016T1 (de) 2007-09-15
CA2246715C (en) 2008-08-05
GB9603507D0 (en) 1996-04-17
US20060018898A1 (en) 2006-01-26
CA2246715A1 (en) 1997-08-28
WO1997031024A1 (en) 1997-08-28
EP0970127A1 (en) 2000-01-12
JP2000506723A (ja) 2000-06-06
DE69738138T2 (de) 2008-06-05
AU1885197A (en) 1997-09-10
DE69738138D1 (de) 2007-10-25
ES2294793T3 (es) 2008-04-01

Similar Documents

Publication Publication Date Title
GB9603507D0 (en) Antibody variants
EP0854917A4 (en) NON-HUMAN TRANSGENIC ANIMALS WHICH MAY PRODUCE HETEROLOGOUS ANTIBODIES
EP0754225A4 (en) HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
MY109957A (en) Improved antibodies to plasmodium falciparum
EP0942959A4 (en) NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
IL97653A0 (en) Catalytic antibody components
NZ595450A (en) Antibodies to M-CSF
EE03285B1 (et) Immuunsust stimuleerivad monoklonaalsed antikehad
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
ATE320448T1 (de) Gereinigte primate clta-8 antigene und verwandte reagenzien
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
IL117942A (en) Antibody purification by low pH hydrophobic interaction chromatography
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
ES2138102T3 (es) Procedimiento para la deteccion de antigeno urinario asociado a tumores.
ATE290597T1 (de) Monoklonale antikörper die die remyelinisierung des zentralnervensystems fördern
NZ237535A (en) Carrier for binding anti-phospholipid antibodies, its use in immunoassays and kits and blood protein which enhances binding ability of antiphospholipid antibody
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
DE3854999D1 (de) An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
IL133881A0 (en) Decreased fat adsorption with an anti-lipase antibody
ES2173879T3 (es) Procedimiento para la preparacion de conjugados a base de un participe especifico en la fijacion y de una proteina que contiene hidratos de carbono
ATE309371T1 (de) Protein mit dnase-aktivität
AU1997897A (en) Nucleic acid-bound polypeptide, method of producing nucleic acid-bound polypeptide, and immunoassay using the polypeptide
NZ314010A (en) A method of targeting intracellular binding proteins using a lipidized antibody

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired